Cullgen’s pipeline of targeted protein degraders is focused primarily on oncology. Our most advanced degrader program is a pan-TRK degrader that is currently under evaluation in a phase I clinical trial for solid tumors. Three of our newer degraders feature the use of novel E3 ligands, and two of our programs have been partnered with Astellas.